GeneDx Holdings Corp (WGS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the WGS SEC filings page.
GeneDx Holdings Corp (WGS) reported $454.4M in revenue over the twelve months to Jun 30, 2026, up 25.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
GeneDx’s dominant shift is from gross-margin expansion to near break-even operations, with FY2025 marking its first positive free-cash-flow year.
Gross margin rose from44.4% in FY2023 to69.7% in FY2025, pointing to a major change in revenue economics rather than mere volume growth. Operating cash flow moved from-$28.5M in FY2024 to positive territory in FY2025, while free cash flow reached$14.3M , showing that improved gross economics began converting into cash after reinvestment.
Revenue grew
The current ratio fell from 3.6x in FY2024 to 2.5x in FY2025, indicating less short-term cushion despite positive cash generation. Accounts receivable nearly doubled to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of GeneDx Holdings Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
GeneDx Holdings Corp has an operating margin of -3.1%, meaning the company loses $3 on every $100 of revenue. This results in a profitability score of 18/100. This is up from -7.6% the prior year.
GeneDx Holdings Corp's revenue surged 40.0% year-over-year to $427.5M, reflecting rapid business expansion. This strong growth earns a score of 94/100.
GeneDx Holdings Corp carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.46, GeneDx Holdings Corp holds $2.46 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
GeneDx Holdings Corp's free cash flow margin of 3.3% results in a low score of 8/100. Capital expenditures of $19.0M absorb a large share of operating cash flow.
GeneDx Holdings Corp posts a -6.8% return on equity (ROE), meaning it loses $7 for every $100 of shareholders' equity. This results in a returns score of 20/100. This is up from -21.3% the prior year.
GeneDx Holdings Corp scores 4.56, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.6B) relative to total liabilities ($215.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
GeneDx Holdings Corp passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
GeneDx Holdings Corp reported a net loss of $21.0M while generating $33.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
GeneDx Holdings Corp reported an operating loss of $13.1M against $2.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
GeneDx Holdings Corp generated $114.4M in revenue in Q2 2026. This represents an increase of 11.4% from the same quarter a year earlier. Against the prior quarter it is up 11.9%.
GeneDx Holdings Corp's EBITDA was -$14.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 227.5% from the same quarter a year earlier. Against the prior quarter it is up 73.8%.
GeneDx Holdings Corp reported -$17.7M in net income in Q2 2026. This represents a decrease of 264.1% from the same quarter a year earlier. Against the prior quarter it is up 72.0%.
GeneDx Holdings Corp earned -$0.60 per diluted share (EPS) in Q2 2026. This represents a decrease of 266.7% from the same quarter a year earlier. Against the prior quarter it is up 72.2%.
Cash & Balance Sheet
GeneDx Holdings Corp recorded an outflow of $39.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 585.6% from the same quarter a year earlier. Against the prior quarter it is down 0.6%.
GeneDx Holdings Corp held $60.3M in cash against $96.8M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
GeneDx Holdings Corp's gross margin was 68.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.
GeneDx Holdings Corp's operating margin was -15.3% in Q2 2026, reflecting core business profitability. This is down 24.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 41.0 percentage points.
GeneDx Holdings Corp's net profit margin was -15.5% in Q2 2026, showing the share of revenue converted to profit. This is down 26.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 46.4 percentage points.
GeneDx Holdings Corp's ROE was -7.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 11.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 17.7 percentage points.
Capital Allocation
GeneDx Holdings Corp invested $19.7M in research and development in Q2 2026. This represents an increase of 30.4% from the same quarter a year earlier. Against the prior quarter it is down 0.7%.
GeneDx Holdings Corp invested $10.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 326.9% from the same quarter a year earlier. Against the prior quarter it is up 56.7%.
Not reported for Q2 2026.
WGS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.4M+11.4% | $102.3M+17.4% | $121.0M+26.5% | $116.7M+51.9% | $102.7M+45.6% | $87.1M+39.6% | $95.6M+66.6% | $76.9M+44.2% |
| Cost of Revenue | $36.2M+13.9% | $34.0M+18.9% | $36.7M+24.8% | $32.2M+10.9% | $31.8M+15.3% | $28.6M+14.5% | $29.4M+10.4% | $29.0M+3.6% |
| Gross Profit | $78.2M+10.3% | $68.2M+16.6% | $84.3M+27.3% | $84.5M+76.7% | $70.9M+65.1% | $58.5M+56.3% | $66.2M+115.3% | $47.8M+89.4% |
| R&D Expenses | $19.7M+30.4% | $19.8M+57.5% | $24.5M+111.8% | $19.8M+70.0% | $15.1M+38.3% | $12.6M+8.7% | $11.6M-5.4% | $11.7M-18.4% |
| SG&A Expenses | $76.0M+62.3% | $74.6M+47.9% | $9.1M-67.8% | $44.4M+65.1% | $46.9M+79.9% | $50.5M+115.4% | $28.1M-11.8% | $26.9M+3.1% |
| Operating Income | -$17.5M-294.8% | -$57.5M-1162.8% | -$14.2M-261.7% | -$3.3M+58.2% | $9.0M+184.7% | -$4.6M+66.7% | $8.8M+134.3% | -$7.8M+81.9% |
| EBITDA | -$14.4M-227.5% | -$54.8M-2229.7% | -$11.5M-206.2% | -$881K+83.6% | $11.3M+227.0% | -$2.4M+80.3% | $10.8M+147.0% | -$5.4M+85.8% |
| Interest Expense | $1.2M+45.0% | $717K+12.0% | $520K-25.5% | $562K-33.3% | $817K-8.6% | $640K+7.2% | $698K+152.4% | $843K-19.9% |
| Income Tax | -$518K-110.6% | $897K+100.7% | -$564K-2250.0% | $247K+625.5% | -$246K-29.5% | $447K+645.1% | -$24K+94.2% | -$47K+72.7% |
| Net Income | -$17.7M-264.1% | -$63.3M-869.8% | -$17.6M-425.3% | -$7.6M+8.1% | $10.8M+137.1% | -$6.5M+67.7% | $5.4M+121.0% | -$8.3M+80.3% |
| EPS (Basic) | -$0.60-257.9% | -$2.16-839.1% | -$0.61-365.2% | -$0.27+12.9% | $0.38+134.5% | -$0.23+70.5% | $0.23+125.0% | -$0.31+81.1% |
| EPS (Diluted) | -$0.60-266.7% | -$2.16-839.1% | -$0.61-365.2% | -$0.27+12.9% | $0.36+132.7% | -$0.23+70.5% | $0.23+125.0% | -$0.31+81.1% |
| Diluted Shares (Avg) | 30M-0.1% | 29M+4.2% | N/A | 29M+6.3% | 30M+11.8% | 28M+8.0% | N/A | 27M+5.1% |
WGS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $481.5M+3.8% | $506.3M+13.4% | $523.7M+24.9% | $493.9M+20.8% | $463.9M+19.2% | $446.4M+13.2% | $419.4M+0.1% | $408.8M-2.0% |
| Current Assets | $246.4M+20.3% | $270.6M+19.8% | $268.3M+35.5% | $237.6M+27.7% | $204.8M+26.3% | $225.8M+38.2% | $198.0M+8.6% | $186.0M+8.3% |
| Cash & Equivalents | $60.3M-18.6% | $93.9M-5.8% | $105.0M+23.2% | $96.0M+65.8% | $74.1M+32.2% | $99.7M+19.2% | $85.2M-14.5% | $57.9M-33.7% |
| Short-Term Investments | $72.2M+19.5% | $76.8M+29.1% | $66.3M+18.4% | $59.1M+0.9% | $60.4M+19.0% | $59.5M+103.3% | $56.0M+83.7% | $58.6M+117.6% |
| Inventory | $17.8M+49.3% | $12.2M-3.3% | $14.0M+31.0% | $10.6M-1.9% | $11.9M+15.6% | $12.7M+9.0% | $10.7M+21.3% | $10.8M+15.2% |
| Accounts Receivable | $83.6M+74.1% | $76.9M+67.3% | $74.4M+97.6% | $60.9M | $48.0M | $46.0M | $37.6M | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.6M-87.3% | $1.6M | $13.5M | $12.8M | $12.9M | N/A | $0 | N/A |
| Total Liabilities | $237.3M+27.1% | $252.2M+33.4% | $215.5M+23.8% | $201.6M-1.3% | $186.7M-4.3% | $189.0M+0.9% | $174.1M-8.7% | $204.3M+25.3% |
| Current Liabilities | $74.6M+4.5% | $87.6M+26.0% | $108.9M+98.7% | $87.6M+13.3% | $71.4M+4.6% | $69.5M+37.1% | $54.8M-6.8% | $77.3M+13.1% |
| Non-Current Liabilities | $162.6M+41.0% | $164.5M+37.7% | $106.6M-10.6% | $114.0M-10.2% | $115.3M-9.0% | $119.5M-12.5% | $119.3M-9.6% | $127.0M+34.2% |
| Long-Term Debt | $96.8M+87.4% | $96.7M+86.8% | $48.2M-7.2% | $51.6M-0.9% | $51.7M-0.9% | $51.8M-1.0% | $51.9M-1.5% | $52.0M+759.8% |
| Total Equity | $244.2M-11.9% | $254.1M-1.3% | $308.2M+25.7% | $292.3M+42.9% | $277.1M+42.8% | $257.4M+24.2% | $245.2M+7.6% | $204.5M-19.6% |
| Retained Earnings | -$1.5B-7.9% | -$1.4B-5.7% | -$1.4B-1.6% | -$1.4B+0.2% | -$1.3B+0.1% | -$1.4B-2.9% | -$1.4B-4.0% | -$1.4B-6.6% |
WGS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.0M-378.1% | -$32.4M-418.3% | -$3.1M+2.9% | $15.8M+458.7% | $10.4M+331.3% | $10.2M+162.0% | -$3.2M+89.3% | -$4.4M+89.3% |
| Depreciation & Amortization | $3.1M+34.8% | $2.7M+22.7% | $2.8M+37.0% | $2.4M-2.1% | $2.3M+34.3% | $2.2M+26.3% | $2.0M-21.5% | $2.4M-53.1% |
| Stock-Based Compensation | $6.3M-18.8% | $9.0M+125.9% | N/A | $10.6M+191.1% | $7.8M+151.4% | $4.0M+983.1% | N/A | $3.6M+743.6% |
| Capital Expenditures | $10.1M+326.9% | $6.5M+5.3% | $4.3M+42.5% | $6.2M+855.4% | $2.4M+75.2% | $6.1M+1283.5% | $3.0M+28.4% | $646K+476.8% |
| Free Cash Flow | -$39.1M-585.6% | -$38.9M-1058.8% | -$7.4M-19.3% | $9.6M+290.3% | $8.1M+237.5% | $4.1M+124.0% | -$6.2M+80.7% | -$5.0M+87.8% |
| Investing Cash Flow | -$5.6M+84.5% | -$17.3M-83.4% | -$11.1M-2033.3% | -$4.7M+39.6% | -$36.4M-60.1% | -$9.4M-1216.0% | -$519K+89.3% | -$7.8M+71.4% |
| Financing Cash Flow | $1.0M+190.5% | $38.6M+181.3% | $23.2M-25.2% | $10.8M-22.9% | $346K+188.5% | $13.7M+3232.0% | $31.0M-34.1% | $14.0M+1633.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
WGS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.4%-0.7pp | 66.7%-0.4pp | 69.7%+0.4pp | 72.4%+10.2pp | 69.0%+8.1pp | 67.1%+7.2pp | 69.2%+15.7pp | 62.2%+14.8pp |
| Operating Margin | -15.3%-24.0pp | -56.2%-51.0pp | -11.8%-21.0pp | -2.8%+7.3pp | 8.7%+23.7pp | -5.2%+16.7pp | 9.2%+53.9pp | -10.1%+70.5pp |
| Net Margin | -15.5%-26.0pp | -61.9%-54.4pp | -14.6%-20.3pp | -6.5%+4.3pp | 10.5%+51.9pp | -7.5%+24.9pp | 5.7%+50.6pp | -10.8%+68.5pp |
| Return on Equity | -7.3%-11.2pp | -24.9%-22.4pp | -5.7%-7.9pp | -2.6%+1.4pp | 3.9%+18.9pp | -2.5%+7.2pp | 2.2%+13.5pp | -4.1%+12.6pp |
| Return on Assets | -3.7%-6.0pp | -12.5%-11.0pp | -3.4%-4.7pp | -1.6%+0.5pp | 2.3%+9.8pp | -1.5%+3.7pp | 1.3%+7.4pp | -2.0%+8.1pp |
| Current Ratio | 3.30+0.4x | 3.09-0.2x | 2.46-1.1x | 2.71+0.3x | 2.87+0.5x | 3.250.0x | 3.61+0.5x | 2.40-0.1x |
| Debt-to-Equity | 0.40+0.2x | 0.38+0.2x | 0.16-0.1x | 0.18-0.1x | 0.19-0.1x | 0.20-0.1x | 0.210.0x | 0.25+0.2x |
| Asset Turnover | 0.240.0x | 0.200.0x | 0.230.0x | 0.240.0x | 0.220.0x | 0.200.0x | 0.23+0.1x | 0.19+0.1x |
| FCF Margin | -34.2%-42.0pp | -38.0%-42.6pp | -6.2%+0.4pp | 8.2%+14.8pp | 7.8%+16.1pp | 4.7%+31.6pp | -6.5%+49.6pp | -6.6%+71.0pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| GeneDx Holdings Corp WGS | FY2025 | $427.5M | -$21.0M | -4.9% | $2.6B | 48/100 |
| Veracyte VCYT | FY2025 | $517.1M | $66.4M | 12.8% | $3.4B | 69/100 |
| Sotera Health Co SHC | FY2025 | $1.2B | $77.9M | 6.7% | $5.4B | 57/100 |
| Radnet RDNT | FY2025 | $2.0B | -$18.6M | -0.9% | $5.8B | 45/100 |
| Guardant Health GH | FY2025 | $982.0M | -$416.3M | -42.4% | $21.7B | 63/100 |
| Charles Riv Labs Intl Inc CRL | FY2025 | $4.0B | -$144.3M | -3.6% | $13.8B | 40/100 |
Where GeneDx Holdings Corp Ranks
Frequently Asked Questions
What is GeneDx Holdings Corp's annual revenue?
GeneDx Holdings Corp (WGS) reported $427.5M in total revenue for fiscal year 2025. This represents a 40.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is GeneDx Holdings Corp's revenue growing?
GeneDx Holdings Corp (WGS) revenue grew by 40.0% year-over-year, from $305.4M to $427.5M in fiscal year 2025.
Is GeneDx Holdings Corp profitable?
No, GeneDx Holdings Corp (WGS) reported a net income of -$21.0M in fiscal year 2025, with a net profit margin of -4.9%.
What is GeneDx Holdings Corp's EBITDA?
GeneDx Holdings Corp (WGS) had EBITDA of -$3.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does GeneDx Holdings Corp have?
As of fiscal year 2025, GeneDx Holdings Corp (WGS) had $105.0M in cash and equivalents against $48.2M in long-term debt.
What is GeneDx Holdings Corp's gross margin?
GeneDx Holdings Corp (WGS) had a gross margin of 69.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is GeneDx Holdings Corp's operating margin?
GeneDx Holdings Corp (WGS) had an operating margin of -3.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is GeneDx Holdings Corp's net profit margin?
GeneDx Holdings Corp (WGS) had a net profit margin of -4.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is GeneDx Holdings Corp's return on equity (ROE)?
GeneDx Holdings Corp (WGS) has a return on equity of -6.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is GeneDx Holdings Corp's free cash flow?
GeneDx Holdings Corp (WGS) generated $14.3M in free cash flow during fiscal year 2025. This represents a 142.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is GeneDx Holdings Corp's operating cash flow?
GeneDx Holdings Corp (WGS) generated $33.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are GeneDx Holdings Corp's total assets?
GeneDx Holdings Corp (WGS) had $523.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are GeneDx Holdings Corp's capital expenditures?
GeneDx Holdings Corp (WGS) invested $19.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does GeneDx Holdings Corp spend on research and development?
GeneDx Holdings Corp (WGS) invested $72.0M in research and development during fiscal year 2025.
What is GeneDx Holdings Corp's current ratio?
GeneDx Holdings Corp (WGS) had a current ratio of 2.46 as of fiscal year 2025, which is generally considered healthy.
What is GeneDx Holdings Corp's debt-to-equity ratio?
GeneDx Holdings Corp (WGS) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is GeneDx Holdings Corp's return on assets (ROA)?
GeneDx Holdings Corp (WGS) had a return on assets of -4.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is GeneDx Holdings Corp's P/E ratio?
GeneDx Holdings Corp (WGS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.6B as of Sep 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GeneDx Holdings Corp's price-to-sales ratio?
GeneDx Holdings Corp (WGS) trades at 5.6x sales, its market capitalization divided by revenue of $454.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.6B as of Sep 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GeneDx Holdings Corp's Altman Z-Score?
GeneDx Holdings Corp (WGS) has an Altman Z-Score of 4.56, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is GeneDx Holdings Corp's Piotroski F-Score?
GeneDx Holdings Corp (WGS) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GeneDx Holdings Corp's earnings high quality?
GeneDx Holdings Corp (WGS) reported a net loss of $21.0M while generating $33.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can GeneDx Holdings Corp cover its interest payments?
GeneDx Holdings Corp (WGS) reported an operating loss of $13.1M against $2.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is GeneDx Holdings Corp?
GeneDx Holdings Corp (WGS) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.